Radiotherapy of glioblastoma 15 years after the landmark
Stupp's trial: more controversies than standards?

J 2018

Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?

KAZDA, Tomáš, Adam DZIACKY, Petr BURKOŇ, Petr POSPÍŠIL, Marek SLÁVIK et. al.

Základní údaje

Originální název

Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?

Autoři

KAZDA, Tomáš (203 Česká republika, domácí), Adam DZIACKY (703 Slovensko, domácí), Petr BURKOŇ (203 Česká republika, domácí), Petr POSPÍŠIL (203 Česká republika, domácí), Marek SLÁVIK (703 Slovensko, domácí), Zdeněk ŘEHÁK (203 Česká republika, domácí), Radim JANČÁLEK (203 Česká republika, domácí), Pavel ŠLAMPA (203 Česká republika, domácí), Ondřej SLABÝ (203 Česká republika, domácí) a Radek LAKOMÝ (203 Česká republika, garant, domácí)

Vydání

RADIOLOGY AND ONCOLOGY, LJUBLJANA, ASSOC RADIOLOGY & ONCOLOGY, 2018, 1318-2099

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30224 Radiology, nuclear medicine and medical imaging

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.846

Kód RIV

RIV/00216224:14110/18:00104694

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.2478/raon-2018-0023

UT WoS

000433103400001

Klíčová slova anglicky

glioblastoma; radiation therapy; controversy; target volumes; radiotherapy dosage

Štítky

14110131, 14110811, 14110812, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 3. 2019 16:02, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Background. The current standard of care of glioblastoma, the most common primary brain tumor in adults, has remained unchanged for over a decade. Nevertheless, some improvements in patient outcomes have occurred as a consequence of modern surgery, improved radiotherapy and up-to-date management of toxicity. Patients from control arms (receiving standard concurrent chemoradiotherapy and adjuvant chemotherapy with temozolomide) of recent clinical trials achieve better outcomes compared to the median survival of 14.6 months reported in Stupp's landmark clinical trial in 2005. The approach to radiotherapy that emerged from Stupp's trial, which continues to be a basis for the current standard of care, is no longer applicable and there is a need to develop updated guidelines for radiotherapy within the daily clinical practice that address or at least acknowledge existing controversies in the planning of radiotherapy. The goal of this review is to provoke critical thinking about potentially controversial aspects in the radiotherapy of glioblastoma, including among others the issue of target definitions, simultaneously integrated boost technique, and hippocampal sparing. Conclusions. In conjunction with new treatment approaches such as tumor-treating fields (TTF) and immunotherapy, the role of adjuvant radiotherapy will be further defined. The personalized approach in daily radiotherapy practice is enabled with modern radiotherapy systems.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

Citovat

KAZDA, Tomáš, Adam DZIACKY, Petr BURKOŇ, Petr POSPÍŠIL, Marek SLÁVIK, Zdeněk ŘEHÁK, Radim JANČÁLEK, Pavel ŠLAMPA, Ondřej SLABÝ a Radek LAKOMÝ. Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards? RADIOLOGY AND ONCOLOGY. LJUBLJANA: ASSOC RADIOLOGY & ONCOLOGY, 2018, roč. 52, č. 2, s. 121-128. ISSN 1318-2099. Dostupné z: https://dx.doi.org/10.2478/raon-2018-0023.

@article{1473156,
   author = {Kazda, Tomáš and Dziacky, Adam and Burkoň, Petr and Pospíšil, Petr and Slávik, Marek and Řehák, Zdeněk and Jančálek, Radim and Šlampa, Pavel and Slabý, Ondřej and Lakomý, Radek},
   article_location = {LJUBLJANA},
   article_number = {2},
   doi = {http://dx.doi.org/10.2478/raon-2018-0023},
   keywords = {glioblastoma; radiation therapy; controversy; target volumes; radiotherapy dosage},
   language = {eng},
   issn = {1318-2099},
   journal = {RADIOLOGY AND ONCOLOGY},
   title = {Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?},
   volume = {52},
   year = {2018}
}

TY  - JOUR
ID  - 1473156
AU  - Kazda, Tomáš - Dziacky, Adam - Burkoň, Petr - Pospíšil, Petr - Slávik, Marek - Řehák, Zdeněk - Jančálek, Radim - Šlampa, Pavel - Slabý, Ondřej - Lakomý, Radek
PY  - 2018
TI  - Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards?
JF  - RADIOLOGY AND ONCOLOGY
VL  - 52
IS  - 2
SP  - 121-128
EP  - 121-128
PB  - ASSOC RADIOLOGY & ONCOLOGY
SN  - 13182099
KW  - glioblastoma
KW  - radiation therapy
KW  - controversy
KW  - target volumes
KW  - radiotherapy dosage
N2  - Background. The current standard of care of glioblastoma, the most common primary brain tumor in adults, has remained unchanged for over a decade. Nevertheless, some improvements in patient outcomes have occurred as a consequence of modern surgery, improved radiotherapy and up-to-date management of toxicity. Patients from control arms (receiving standard concurrent chemoradiotherapy and adjuvant chemotherapy with temozolomide) of recent clinical trials achieve better outcomes compared to the median survival of 14.6 months reported in Stupp's landmark clinical trial in 2005. The approach to radiotherapy that emerged from Stupp's trial, which continues to be a basis for the current standard of care, is no longer applicable and there is a need to develop updated guidelines for radiotherapy within the daily clinical practice that address or at least acknowledge existing controversies in the planning of radiotherapy. The goal of this review is to provoke critical thinking about potentially controversial aspects in the radiotherapy of glioblastoma, including among others the issue of target definitions, simultaneously integrated boost technique, and hippocampal sparing. Conclusions. In conjunction with new treatment approaches such as tumor-treating fields (TTF) and immunotherapy, the role of adjuvant radiotherapy will be further defined. The personalized approach in daily radiotherapy practice is enabled with modern radiotherapy systems.
ER  -

KAZDA, Tomáš, Adam DZIACKY, Petr BURKOŇ, Petr POSPÍŠIL, Marek SLÁVIK, Zdeněk ŘEHÁK, Radim JANČÁLEK, Pavel ŠLAMPA, Ondřej SLABÝ a Radek LAKOMÝ. Radiotherapy of glioblastoma 15 years after the landmark Stupp's trial: more controversies than standards? \textit{RADIOLOGY AND ONCOLOGY}. LJUBLJANA: ASSOC RADIOLOGY \&{}amp; ONCOLOGY, 2018, roč.~52, č.~2, s.~121-128. ISSN~1318-2099. Dostupné z: https://dx.doi.org/10.2478/raon-2018-0023.

Podrobný výpis o publikaci